Semra Paydas
The oncogene encoding Her2 receptor which has an important biologic significance in human cancers has been described 30 years ago by Schecter et al. Her2 amplification in gastric cancer has been shown in MKN-7 gastric cancer cell line firstly by Fukushige et al. in 1986. Later studies showed variable expression of ERBB2 in gastric cancer and Her2 expression rate has been found between 8% and 54%. Significant survival advantage has been reported with the introduction of trastuzumab in cases with gastric cancer expressing ERBB2. Other anti-ERBB2 agents are used in ongoing studies and longer survival times are expected. By analogy with ERBB2 breast cancer it can be speculated that central nervous system metastases may increase in these cases with increased survival times. Here we reported brain metastases in a case with metastatic gastric cancer treated by trastuzumab containing regimen.
分享此文章
English 
Spanish 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi 